By Deena Beasley (Reuters) -Adding Amgen's cholesterol drug Repatha to standard therapy reduced major cardiovascular events ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of ...

A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack— doesn’t benefit the vast majority of patients and may contribute to a higher risk of ...

Semaglutide, the active ingredient in Wegovy and Ozempic, lowers major cardiac event risk, regardless of how much weight a person loses while taking the GLP-1 medication, a new study finds.

Aficamten shows cardiac benefits over blood pressure drug metoprolol Analysts see potential for aficamten to replace beta-blocker drugs for treating HCM Cytokinetics plans to submit data to regulators ...

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by ...

Atorvastatin, one of the world’s most widely prescribed cholesterol-lowering drugs, has played a major role in reducing heart ...

Bristol Myers Squibb BMY suffered a setback in the late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos (mavacamten). The phase III study was evaluating Camzyos for the treatment of ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

CHICAGO — A nasal spray formulation of bumetanide, a diuretic drug, could help treat heart failure by preventing the resistance that can develop to oral forms of the drug, a preliminary safety and ...

This little pill — taken by adults and children alike — might just be a prescription for heart disease. Speaking to The Post, the veteran heart doctor tackled a drug that is commonly prescribed to ...